Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Patients with nonexudative (“dry”) age‐related macular degeneration (AMD) frequently also develop neovascular (“wet”) AMD, suggesting a common pathomechanism. Increased vascular endothelial growth factor A (VEGF‐A) has been implicated in the pathogenesis of choroidal neovascularization (CNV) in neovascular AMD, while its role in nonexudative AMD that manifests with progressive retinal pigment epithelium (RPE) and photoreceptor degeneration is not well defined. Mice with overall increased VEGF‐A levels develop progressive morphological features of both forms of AMD, suggesting that an increase in VEGF‐A has a direct age‐dependent adverse effect on RPE and photoreceptor function independently of its CNV‐promoting proangiogenic effect. Here we provide evidence for this hypothesis and show that morphological RPE abnormalities and retinal thinning in mice with increased VEGF‐A levels correlate with progressive age‐dependent attenuation of visual function with abnormal electroretinograms and reduced retinal rhodopsin levels. Retinoid profiling revealed a progressive reduction of 11‐ cis and all‐trans retinal in the retinas of these mice, consistent with an impaired retinoid transport between the RPE and photoreceptors. These findings suggest that increased VEGF‐A leads to an age‐dependent RPE and retinal dysfunction that occurs also at sites where no CNV lesions form. The data support a central role of increased VEGF‐A not only in the pathogenesis of neovascular but also of nonexudative AMD.—Ablonczy, Z., Dahrouj, M., Marneros, A. G. Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF‐A levels. FASEB J . 28, 2369–2379 (2014). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“and increased VEGF-A levels are causally implicated in the progressive dysfunction of the RPE [ 46 ].”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669 · cited 1×
“Anti-VEGF-A treatments are currently the mainstay of therapy for neovascular AMD (26).”
BackgroundBird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023 · cited 1×
“However, it has recently been reported that neovascular AMD disease progression often occurs despite long-term treatment with anti-VEGF-A therapies and that long-term antiVEGF-A treatments can be associated with macular atrophy (27).”
BackgroundThe epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932
Photoreceptor loss in age-related macular degeneration.
Curcio, C. A., Medeiros, N. E., & Millican, C. L. (1996) · PubMed · Cited by 924
Seven new loci associated with age-related macular degeneration
The AMD Gene Consortium (2013) · Nature Genetics · doi:10.1038/ng.2578 · Cited by 788
Spilsbury, K., Garrett, K. L., Shen, W.-Y., Constable, I. J., & Rakoczy, P. E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64525-7 · Cited by 394 · cited 1×
“Overexpression of VEGF-A(164) in the RPE via adenoviral delivery has previously been reported to result in CNV lesions, which strongly resemble those observed here in the VEGF-A mice, providing further evidence that the observed abnormalities in VEGF-A mice are indeed due to increased VEGF-A levels and not due to othe…”
ResultBasal Linear Deposit and Large Drusen Are Specific for Early Age-Related Maculopathy
Curcio, C. A. (1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.3.329 · Cited by 386
Cited by
Whitmore, S. S., Sohn, E. H., Chirco, K. R., Drack, A. V., Stone, E. M., Tucker, B. A., & Mullins, R. F. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.11.005 · Cited by 218
“Several of these processes, such as increased ICAM1 and a role for VEGF upregulation (Ablonczy et al., 2014) have been proposed in AMD.”
BackgroundNguyen, D. D., Luo, L.-J., Yang, C.-J., & Lai, J.-Y. (2023) · ACS Nano · doi:10.1021/acsnano.2c05824 · Cited by 213
Marazita, M. C., Dugour, A., Marquioni-Ramella, M. D., Figueroa, J. M., & Suburo, A. M. (2016) · Redox Biology · doi:10.1016/j.redox.2015.11.011 · Cited by 207
“Inter-estingly, recent studies in a VEGF-hyperexpressing mouse strain suggest that this factor might also be involved in nonexudative AMD pathogenesis [80].”
Holz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Hykin, P., Staurenghi, G., Wittrup-Jensen, K., Altemark, A., Nilsson, J., et al. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308166 · Cited by 124
NLRP3 Inflammasome and Pathobiology in AMD
Celkova, L., Doyle, S., & Campbell, M. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4010172 · Cited by 104
“A recently described VEGF-based transgenic mouse model for AMD suggested that increased VEGF alone is sufficient to cause both forms of the disease [52,111].”
BackgroundINTEGRITY OF OUTER RETINAL LAYERS AFTER RESOLUTION OF CENTRAL INVOLVED DIABETIC MACULAR EDEMA
Müftüoğlu, İ. K., Mendoza, N., Gaber, R. A., Alam, M. M. R., You, Q. S., & Freeman, W. R. (2017) · Retina · doi:10.1097/iae.0000000000001459 · Cited by 77
Monomeric C‐reactive protein and inflammation in age‐related macular degeneration
Chirco, K. R., Whitmore, S. S., Wang, K., Potempa, L. A., Halder, J. A., Stone, E. M., Tucker, B. A., & Mullins, R. F. (2016) · The Journal of Pathology · doi:10.1002/path.4766 · Cited by 58
“Upon major loss of vasculature, the surrounding tissue can become hypoxic, leading to increased ICAM-1 expression on the remaining endothelial cells [47,48] as well as elevated levels of VEGF in the choriocapillaris [56,57].”
BackgroundProgressive Early Breakdown of Retinal Pigment Epithelium Function in Hyperglycemic Rats
Desjardins, D. M., Yates, P. W., Dahrouj, M., Liu, Y., Crosson, C. E., & Ablonczy, Z. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18397 · Cited by 70
“The most compelling evidence being the RPE breakdown observed in VEGF transgenic animals.(35,36) A similar process is consistent with diabetes, where ocular VEGF is known to be induced.”
BackgroundSelf-citationMAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Moustardas, P., Aberdam, D., & Lagali, N. (2023) · Cells · doi:10.3390/cells12040617 · Cited by 63
“VEGF is known to be the major angiogenic factor involved in AMD [45], and increased VEGF-A levels are causally implicated in the progressive dysfunction of the RPE [46].”
BackgroundHolz, F. G., Tadayoni, R., Beatty, S., Berger, A. R., Cereda, M. G., Hykin, P. G., Staurenghi, G., Wittrup-Jensen, K. U., Nilsson, J., Kim, K., et al. (2016) · Eye · doi:10.1038/eye.2016.90 · Cited by 63
Freund, K. B., Balaratnasingam, C., Dhrami‐Gavazi, E., McCann, J., & Ghadiali, Q. (2015) · Clinical ophthalmology · doi:10.2147/opth.s80040 · Cited by 61
“20 The shift may also be consequent to diseases that modulate the function of a normal population of cells through feedback mechanisms without altering cell structure and density.”
Increased VEGF‐A promotes multiple distinct aging diseases of the eye through shared pathomechanisms
Marneros, A. G. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505613 · Cited by 55
“…in eyes of all VEGF-Ahyper mice examined (> 400 mice were examined in total, between ages 6 weeks to 34 months) an age-dependent manifestation of AMD-like pathologies with CNV and progressive RPE/photoreceptor degeneration (Fig 5, Appendix Figs S2 and S3) (Marneros, 2013; Ablonczy et al, 2014).”
BackgroundMethodSelf-citationIbuki, M., Lee, D., Shinojima, A., Miwa, Y., Tsubota, K., & Kurihara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238940 · Cited by 51
“The development of AMD involves complex pathological mechanisms.”
BackgroundInfluentialManagement and Outcomes for Neovascular Age-Related Macular Degeneration
Kiss, S., Campbell, J. H., Almony, A., Shih, V., Serbin, M., LaPrise, A., & Wykoff, C. C. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.02.027 · Cited by 50
Schnabolk, G., Parsons, N., Obert, E., Annamalai, B., Nasarre, C., Tomlinson, S., Lewin, A. S., & Rohrer, B. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.003 · Cited by 39
Role of inflammasome activation in neovascular age‐related macular degeneration
Marneros, A. G. (2021) · FEBS Journal · doi:10.1111/febs.16278 · Cited by 39
Self-citationWeber, M., Velasque, L., Coscas, F., Faure, C., Aubry, I., & Cohen, S. Y. (2019) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2017-000109 · Cited by 37
“RAINBOW is an ongoing, observational, 4-year study to monitor the effectiveness and safety of IVT-AFL in treatment-naïve patients with wet AMD.”
BackgroundInfluentialRetinal pigment epithelial cells as a therapeutic tool and target against retinopathies
Pavan, B., & Dalpiaz, A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.06.009 · Cited by 33
Sivaprasad, S., Hykin, P., Chakravarthy, U., Lotery, A., McKibbin, M., & Napier, J. (2016) · Clinical Ophthalmology · doi:10.2147/opth.s92627 · Cited by 31
“Introduction The current standard of care for neovascular age-related macular degeneration (nAMD) is treatment with agents (such as ranibizumab) that inhibit vascular endothelial growth factor (VEGF), a potent angiogenic mediator associated with age-dependent choroidal neovascularization.(1) Ranibizumab was approved f…”
Fields, M. A., Bowrey, H. E., Gong, J., Moreira, E. F., Cai, H., & Priore, L. V. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177763 · Cited by 31
HIF Inhibition Therapy in Ocular Diseases
Lee, D., Miwa, Y., Kunimi, H., Ibuki, M., Shoda, C., Nakai, A., & Kurihara, T. (2021) · The Keio Journal of Medicine · doi:10.2302/kjm.2021-0004-ir · Cited by 30
Visualization of Mouse Choroidal and Retinal Vasculature Using Fluorescent Tomato Lectin Perfusion
Jiao, C., Adler, K., Liu, X., Sun, W., Mullins, R. F., & Sohn, E. H. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.1.1 · Cited by 25
Malsy, J., Alvarado, A. C., Lamontagne, J. O., Strittmatter, K., & Marneros, A. G. (2020) · eLife · doi:10.7554/elife.60194 · Cited by 25
“Immunolabeling and choroidal flat mounting CNV lesions in mice with the Vegfa allele can be accurately quantitated in choroidal flat mounts by co-labeling with phalloidin and immunolabeling for the endothelial cell marker CD31: (1) neovessels in CNV lesions show strongly increased CD31 labeling (allowing distinction f…”
BackgroundSelf-citationHistone Deacetylase Inhibition Restores Retinal Pigment Epithelium Function in Hyperglycemia
Desjardins, D. M., Liu, Y., Crosson, C. E., & Ablonczy, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162596 · Cited by 25
“As expected from our previous studies [17, 39], following 6 h incubation with VEGF, TEER was significantly decreased.”
BackgroundResultSelf-citationIzawa, H., Inoue, Y., Ohno, Y., Ojino, K., Tsuruma, K., Shimazawa, M., & Hara, H. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16748 · Cited by 21
“Moreover, increased VEGF levels in the RPE of VEGF mice caused RPE disfunction and not the choriocapillaris.(45,46) These reports suggested that VEGF can disrupt RPE barrier directly, in either a paracrine or an autocrine manner.”
BackgroundSchranz, M. W., Told, R., Häcker, V., Reiter, G. S., Reumueller, A., Vogl, W., Bogunović, H., Sacu, S., Schmidt-Erfurth, U. M., & Roberts, P. K. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15219 · Cited by 20
“One hypothesis could be that SRF and IRF might derive from a combination of increased permeability of physiological retinal vessels and RPE dysfunction due to abnormal VEGF levels (Ablonczy et al., 2014).”
BackgroundVEGF-A and the NLRP3 Inflammasome in Age-Related Macular Degeneration
Marneros, A. G. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17121-0_12 · Cited by 19
Self-citationExploring the role of VEGF in Indian age-related macular degeneration
Sharma, K., Sharma, N. K., Singh, R., & Anand, A. (2015) · Annals of Neurosciences · doi:10.5214/ans.0972.7531.220408 · Cited by 16
Apr3 accelerates the senescence of human retinal pigment epithelial cells
Han, S., Lu, Q., & Wang, N. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4926 · Cited by 16
“Increased expression of vascular endothelial growth factor (VEGF) and pigment epithelial-derived factor (PEDF) by RPE were identified in AMD and are effective therapeutic targets for AMD (3,13,14).”
Weber, M., Kodjikian, L., Coscas, F., Faure, C., Aubry, I., Dufour, I., & Cohen, S. Y. (2020) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2019-000377 · Cited by 16
Solberg, Y., Dysli, C., Escher, P., Berger, L., Wolf, S., & Zinkernagel, M. S. (2019) · Ophthalmologica · doi:10.1159/000503567 · Cited by 14
Yanagi, Y., Fukuda, A., Barzey, V., & Adachi, K. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1245196 · Cited by 14
“Parameters considered were: (1) the number of ranibizumab injections; (2) treatment maintenance from year 3 to year 5; (3) estimated utility values (the utility data derived from method 1); (4) discontinuation rate; (5) analysis time horizon; (6) cost of blindness; (7) adverse event rate; (8) patient age; and (9) the…”
BackgroundKang, E. C., Seo, Y., & Byeon, S. H. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3336-8 · Cited by 11
“Increased VEGF-A levels in mice were found to contribute to anatomical changes in RPE cells and retinal thinning [28].”
BackgroundLivnat, T., Weinberger, Y., Fernández, J. A., Alaa, B., Ben-David, G., Palevski, D., Levy‐Mendelovich, S., Kenet, G., Budnik, I., Nisgav, Y., et al. (2021) · Biomolecules · doi:10.3390/biom11030358 · Cited by 11
“In the aging eye, the pathologic level of VEGF released by the RPE was a detrimental factor in developing CNV and neovascular age-related macular degeneration nAMD [1,22].”
BackgroundSpooner, K., Fraser‐Bell, S., Hong, T., & Chang, A. (2019) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13636 · Cited by 11
“BCVA outcomes are resultant upon multiple factors that influence the function of the retinal pigment epithelium and photoreceptors.(30,31) Loss of vision caused by severe macular oedema may be partially reversible depending upon the level of damage to the neural retina.”
BackgroundWang, H., Kunz, E., Stoddard, G. J., Hauswirth, W. W., & Hartnett, M. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-52163-z · Cited by 9
Meng, Y., Zhang, T., Sun, Y., Yi, S., Han, G., Wei, P., Chen, X., Wang, Y., & Zhu, L. Y. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.5c03180 · Cited by 8
Montesel, A., Hagag, A. M., Chandra, S., Muhammed, R. P., Thottarath, S., Chandak, S., & Sivaprasad, S. (2023) · Eye · doi:10.1038/s41433-023-02574-0 · Cited by 8
“Further improvements in OCTA resolution, as well as the validation of standard operative parameters, could reduce investigator-related bias and further re fi ne the reliability of the clinical applications of computational tools.”
BackgroundEvaluation of a connexin-based peptide for the treatment of age-related macular degeneration
Obert, E., Grek, C. L., Ghatnekar, G. S., & Rohrer, B. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11359 · Cited by 8
“RPE breakdown is thought to be mediated by elevated levels of vascular endothelial growth factor (VEGF) in wet, and possibly in dry AMD (Ablonczy et al., 2014; Cachafeiro et al., 2013).”
BackgroundKozlowski, M. R. (2014) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2014.0071 · Cited by 8
“Prolonged overexpression of VEGF can also produce CNV, and this effect may, likewise, depend on a reduction of the barrier properties of the RPE layer induced by VEGF.(7,38,39) If the barrier properties of the human RPE cells in aged eyes are compromised by an increased responsiveness to VEGF brought on by cell senesc…”
InfluentialIntravitreal aflibercept protects photoreceptors of mice against excessive light exposure
Kuse, Y., Takahashi, K., Inoue, Y., Izawa, H., Nakamura, S., Shimazawa, M., & Hara, H. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.07.010 · Cited by 7
Progranulin increases phagocytosis by retinal pigment epithelial cells in culture
Murase, H., Tsuruma, K., Kuse, Y., Shimazawa, M., & Hara, H. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24081 · Cited by 7
“The RPE maintains the homeostasis of the retina and choroid (Ablonczy et al., 2014).”
BackgroundParsons, N., Annamalai, B., & Rohrer, B. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.7.17 · Cited by 6
Chen, C., Yang, X., Jiang, Z., Wang, M., Li, X., Huang, H., Li, M., Liu, Y., Liu, Z., Deng, Y., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.11.37 · Cited by 4
“56,57 Although most anti-VEGF therapies reduce neovascularization and inflammation, they rarely restore retinal function.”
Chen, N.-N., Chen, C.-Y., Wang, J.-J., Huang, H.-C., Chen, W.-D., Chen, C., Yang, Y.-H., Lin, M., Kuo, T., & Lai, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087285 · Cited by 4
“Abbreviations: CMT, central macular thickness; EZ, ellipsoid zone; HRDs, hyperreflective dots; IRC, intraretinal cysts; MAR, the minimum angle of resolution; RPED, retinal pigment epithelium detachment; SHRM, subretinal hyperreflective material; and SRF, subretinal fluid.”
BackgroundInfluentialJu, R.-H., He, M.-S., Hou, J., Li, M., Zhang, J., & Wu, Z. (2017) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2017.07.14 · Cited by 4
Jensen, E. G., Jakobsen, T. S., Schnabolk, G., Wilson, K., Rask-Pedersen, M., Jensen, N. M., Andersen, G. R., Thiel, S., Aagaard, L., Rohrer, B., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101620 · Cited by 3
RPE and the Vascular Endothelial Growth Factor
Klettner, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-28384-1_5 · Cited by 3
Holz, F. G., Tadayoni, R., Beatty, S., Berger, A. R., Cereda, M. G., Hykin, P. G., Staurenghi, G., Wittrup-Jensen, K., Nilsson, J., Kim, K., et al. (2017) · Eye · doi:10.1038/eye.2016.276 · Cited by 3
Small Noncoding RNA in Regulation of Differentiation of Retinal Pigment Epithelium
Kuznetsova, A. V., Rzhanova, L. A., & Aleksandrova, M. A. (2021) · Russian Journal of Developmental Biology · doi:10.1134/s106236042103005x · Cited by 2
Real-world utilization of ranibizumab in wet age-related macular degeneration patients from Canada
Devenyi, R. G., Maberley, D., Sheidow, T., Tourville, É., Brunck, L. R., & Berger, A. R. (2016) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2015.11.008 · Cited by 1
“Although AMD is a degenerative condition linked to aging,(2) the most progressive form is associated with increased vascular endothelial growth factor (VEGF), a potent angiogenic mediator.(2,3) This has resulted in the development and widespread use of anti-VEGF agents, such as ranibizumab, which was approved for use…”
BackgroundOsmolyte taurine induction in UVA exposed human retinal pigment epithelial cells
Dayang, W., & Dong-bo, P. (2018) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2018.1465078 · Cited by 1
RPE und der vaskuläre endotheliale Wachstumsfaktor (VEGF)
Klettner, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-35055-9_5
Xing, P., Zhang, Y., Zhang, Y., Wang, S., Hu, X., Wang, M., Xia, F., Zhao, Y., Qu, W., & Meng, B. (2024) · Clinical ophthalmology · doi:10.2147/opth.s487248
“24,25 Other factors like initial CRT, visual function, age, treatment, RVO type, and BRB breakdown can also affect final BCVA.”
Background
Metadata
- Authors
- Ablonczy, Z., Dahrouj, M., & Marneros, A. G.
- Affiliations
- Medical University of South Carolina (US)
- Harvard University (US)
- Corresponding author
- Marneros, Alexander G.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2014-02-20
- Volume
- 28
- Issue
- 5
- Pages
- 2369-2379
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC3986839
- OpenAlex
- W2161400914
- Cited by
- 52
- References
- 27
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 11 · 2015: 6 · 2014: 2
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The FASEB Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (NEI R01‐EY019297, NEI R01‐EY019065, T32 GM008716)
- Medical University of South Carolina
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- VEGF-A, age-related macular degeneration, retinal pigment epithelium, photoreceptor degeneration, choroidal neovascularization, retinoid transport, rhodopsin, retinal thinning, visual function, retinal degeneration, mouse model
- MeSH terms
- Animals, Electroretinography, Fundus Oculi, Gene Expression Regulation, Macular Degeneration, Male, Mice, Inbred C57BL, Mice, Transgenic, Microscopy, Electron, Retina, Retinoids, Rhodopsin, Vision, Ocular, Signal Transduction, Oxidative Stress, Choroidal Neovascularization, Vascular Endothelial Growth Factor A, Mice, Retinal Pigment Epithelium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.